R & D daily essence pharmaceutical terminates two products R & D to cure diabetes or hope.

The application for clinical trial of Lizhu medicine's monoclonal antibody IL-17A / F was approved; the combination therapy of ADC for bladder cancer was recognized by FDA as a breakthrough therapy; the research found a new mechanism for malaria to escape from the immune system; the new research revealed the role of non coding genes in the formation of atherosclerosis We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On the evening of 19, the essence pharmaceutical announced that it signed the cooperation and authorization agreement with Kadmon Corporation LLC in October 29, 2015 to cooperate in the development of VEGFR-2 monoclonal antibody and PDL-1 monoclonal antibody product Essence pharmaceutical said, as of now, the two products are still in pre clinical research and development stage, the research results and progress do not meet the project expectations, decided to terminate the project's R & D work Recently, the clinical trial application of "recombinant anti-human IL-17A / F humanized monoclonal antibody injection" jointly declared by Lizhu mAb and xinkanghe biological Co., Ltd was approved by the drug administration, Lizhu pharmaceutical announced on Tuesday Indications: moderate to severe plaque psoriasis Today, novel coronavirus has been received by the State Council recently, the office of the State Council to tackle the new type of coronavirus infection, the joint defense joint control mechanism (Research Group), the letter on the recommended test reagent emergency project, the product entered the emergency examination and approval channel, and the two products recommended by Wanfu biological declaration entered the emergency examination and approval channel On the 20th, Seattle genetics and Ansteel announced that the US FDA has granted its antibody coupled drug padcev and pembrolizumab as a breakthrough combination therapy to treat patients with locally advanced or metastatic urothelial carcinoma as a first-line therapy On the 18th, the application for listing of dotiravir / lamivudine, an anti AIDS drug of GlaxoSmithKline, was proposed to be included in the list of priority varieties The drug is the first complete, once-a-day single tablet two drug program approved by FDA If it is successfully included in the priority review process, it is expected to be approved and listed in China as soon as possible Recently, monopar therapeutics announced that the European Commission has granted camsirubicin (mnpr-201; gpx-150; 5-imino-13-deoxydorubicin) the orphan drug qualification (odd) for the treatment of soft tissue sarcoma Recently, the research team at Caltech found that abnormal proteins in the gastrointestinal tract can not only spread to the brain to cause pathological changes, but also easily affect the motor function of old mice It is helpful to improve the symptoms by clearing the abnormal protein in gastrointestinal tract According to a recent study published in the Journal eLife, Plasmodium can recognize a molecule produced by immune cells and then use it to protect itself from damage to the immune system A novel coronavirus pneumonia patient with renal insufficiency was recently reviewed By reviewing 59 cases of renal function cases with new crown virus infection, 63% of the patients showed proteinuria, suggesting renal insufficiency and other clinical features, and 100% of the patients showed abnormal renal imaging in CT scan Recently, researchers at the Korean Academy of science and technology have identified a mechanism for the transfer of acquired resistance to first-line chemotherapy to second-line targeted treatment, which leads to the "domino effect" of cancer resistance In a recent study, researchers from the Wellcome Sanger Institute created the first detailed cell map of human colon immune cells and intestinal bacteria, showing changes in bacterial microbiome and immune cells throughout the colon Recently, Professor Mark Feinberg and others in the Department of cardiovascular medicine of Harvard University revealed the role of non coding genes in the formation of atherosclerosis Atherosclerosis is a kind of heart disease, which is caused by the hardening and narrowing of blood vessels, the obstruction of blood flow Recently, bioengineers at the University of California, San Diego, have developed a control system that makes car T-cell therapy safer and more effective in treating cancer.